Tardive dyskinesia and withdrawal emergent syndrome in children

References

• Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin. Neuropharmacol.18(3), 197–214 (1995).
   PubMed Web of Science ®Google Scholar
• Rodnitzky RL. Drug-induced movement disorders in children and adolescents. Expert Opin. Drug Saf.4(1), 91–102 (2005).
   PubMedGoogle Scholar
• Fahn S. The tardive dyskinesias. In: Recent Advances in Clinical Neurology, Volume 4. Matthews WB, Glaser GH (Eds). Churchill Livingstone, Edinburgh, UK 229–260 (1984).
   Google Scholar
• Klawans HL, Brandabur MM. Chorea in childhood. Pediatr. Ann.22(1), 41–46, 49–50 (1993).
   Google Scholar
• Wolf DW, Wagner KD. Tardive dyskinesia, tardive dystonia, and tardive Tourette’s syndrome in children and adolescents. J. Child Adolesc. Psychopharmacol.3(4), 175–198 (1993).
   Google Scholar
• Stacy M, Cardoso F, Jankovic J. Tardive stereotopy and other movement disorders in tardive dyskinesia. Neurology43(5), 937–941 (1993).
   PubMed Web of Science ®Google Scholar
• Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J. Autism Child. Schizophr.3(3), 247–253 (1973).
   PubMedGoogle Scholar
• Paulson GW, Rizvi CA, Crane GE. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin. Pediatr.14(10), 953–955 (1975).
   Web of Science ®Google Scholar
• Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. Arch. Gen. Psychiatry43(4), 335–340 (1986).
   PubMed Web of Science ®Google Scholar
• Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J. Am. Acad. Child. Adolesc. Psychiatry36(6), 835–843 (1997).
   PubMed Web of Science ®Google Scholar
• Kumra S, Jacobsen LK, Lenane M et al. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia. J. Am. Acad. Child. Adolesc. Psychiatry37(2), 221–227 (1998).
   PubMed Web of Science ®Google Scholar
• Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur. Child. Adolesc. Psychiatry15(2), 97–104 (2006).
   PubMed Web of Science ®Google Scholar
• Wonodi I, Reeves G, Carmichael D et al. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov. Disord.22(12), 1777–1782 (2007).
   PubMed Web of Science ®Google Scholar
• McAndrew Case Q, Treffert DA. Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. J. Autism Child. Schizophr.2(1), 75–91 (1972).
   PubMedGoogle Scholar
• Browning DH, Ferry PC. Tardive dyskinesia in a ten-year-old boy: an undesirable sequel of phenothiazine medication. Clin. Pediat.15(10), 955–957 (1976).
   Google Scholar
• Caine ED, Margolin DI, Brown GL, Ebert MH. Gilles de la Tourette’s syndrome, tardive dyskinesia, and psychosis in an adolescent. Am. J. Psychiatry135(2), 241–242 (1978).
   PubMedGoogle Scholar
• McLean P, Casey DE. Tardive dyskinesia in an adolescent. Am. J. Psychiatry135(8), 969–971 (1978).
   Google Scholar
• Mizrahi EM, Holtzman D, Tharp B. Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette’s disease. Arch. Neurol.37(12), 780 (1980).
   PubMedGoogle Scholar
• Caine ED, Polinsky RJ. Tardive dyskinesia in persons with Gilles de la Tourette’s disease. Arch. Neurol.38(7), 471–472 (1981).
   PubMedGoogle Scholar
• Putnam PE, Orenstein SR, Wessel HB, Stowe RM. Tardive dyskinesia associated with use of metoclopramide in a child. J. Pediatr.121(6), 983–985 (1992).
   PubMed Web of Science ®Google Scholar
• Kompoliti K, Goetz C. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov. Disord.13(3), 477–480 (1998).
   PubMed Web of Science ®Google Scholar
• Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J. Clin. Psychiatry59(9), 472–477 (1998).
   PubMedGoogle Scholar
• Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov. Disord.20(1), 86–89 (2005).
   PubMed Web of Science ®Google Scholar
• Gualtieri CT, Quade D, Hicks RE, Mayo JP, Schroeder SR. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am. J. Psychiatry141(1), 20–23 (1984).
   PubMed Web of Science ®Google Scholar
• Perry R, Campbell M, Green WH et al. Neuroleptic-related dyskinesias in autistic children: a prospective study. Psychopharmacol. Bull.21(1), 140–143 (1985).
   Google Scholar
• Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol. Bull.24(2), 251–255 (1988).
   PubMedGoogle Scholar
• Malone RP, Ernst M, Godfrey KA, Locascio JJ, Campbell M. Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacol. Bull.27(2), 113–117 (1991).
   Google Scholar
• Shay J, Sanchez LE, Cueva JE, Armenteros J, Overall JE, Campbell M. Neuroleptic-related dyskinesias and stereotypies in autistic children: videotaped ratings. Psychopharmacol. Bull.29(3), 359–363 (1993).
   Google Scholar
• Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol. Bull.31(2), 363–369 (1995).
   PubMedGoogle Scholar
• MacEwan T, Morton MJS. Use of clozapine in a child with treatment-resistant schizophrenia. Br. J. Psychiatry168(3), 376–378 (1996).
   Google Scholar
• Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J. Pediatr.69(4), 589–595 (1966).
   PubMed Web of Science ®Google Scholar
• Tamer A, McKey R, Arias D, Worley L, Fogel BJ. Phenothiazine-induced extrapyramidal dysfunction in the neonate. J. Pediatr.75(3), 479–480 (1969).
   PubMed Web of Science ®Google Scholar
• Holmes C, Flaherty R. Trimethobenzamide Hcl (Tigan)-induced extrapyramidal dysfunction in a neonate. J. Pediatr.89(4), 669–670 (1976).
   Google Scholar
• Gualtieri CT, Barnhill J, McGimsey J, Schell D. Tardive dyskinesia and other movement disorders in children treated with psychotropic drugs. J. Am. Acad. Child Psychiatry19(3), 491–510 (1980).
   Google Scholar
• Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J. Perinatol.9(2), 170–172 (1989).
   Google Scholar
• Rosebush PI, Kennedy K, Dalton BM Mazurek MF. Protracted akathisia after risperidone withdrawal. Am. J. Psychiatry154(3), 437–438 (1997).
   PubMed Web of Science ®Google Scholar
• Giladi N, Shabtai H. Melatonin-induced withdrawal emergent dyskinesia and akathisia. Mov. Disord.14(2), 381–382 (1999).
   Google Scholar
• Lore C. Risperidone and withdrawal dyskinesia. J. Am. Acad. Child. Adolesc. Psychiatry39(8), 941 (2000).
   Google Scholar
• Connor DF, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J. Clin. Psychiatry62(12), 967–974 (2001).
   PubMed Web of Science ®Google Scholar
• McCracken JT, McGough J, Shah B et al. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med.347(5), 314–321 (2002).
   PubMed Web of Science ®Google Scholar
• Brasic JR, Barnett JY, Kowalik S, Tsaltas MO, Ahmad R. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic. Psychol. Rep.95(3 Pt 2), 1079–1086 (2004).
   PubMed Web of Science ®Google Scholar
• Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J. Child Adolesc. Psychopharmacol.18(4), 337–345 (2008).
   Web of Science ®Google Scholar
• Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med. Princ. Pract.17, 415–418 (2008).
   PubMed Web of Science ®Google Scholar
• Silverstein FS, Johnston MV. Risks of neuroleptic drugs in children. J. Child Neurol.2(1), 41–43 (1987).
   Google Scholar
• Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. Am. J. Psychiatry145(5), 621–624 (1988).
   Google Scholar
• Kasantikul D, Kanchanatawan B. Antipsychotic-induced tardive movement disorders: a series of twelve cases. J. Med. Assoc. Thai.90(1), 188–194 (2007).
   PubMedGoogle Scholar
• Woerner MG, Kane JM, Lieberman JA et al. The prevalence of tardive dyskinesia. J. Clin. Psychopharmacol.11(1), 34–42 (1991).
   PubMed Web of Science ®Google Scholar
• Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch. Intern. Med.153(12), 1469–1475 (1993).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Stereotypies in autistic and other childhood disorders. In: Paediatric Movement Disorders. Fernandez Alvarez E, Arzimanoglou A, Tolosa E (Eds). John Libbey Eurotex Limited, Montrouge, France 247–260 (2005).
   Google Scholar
• Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J. Clin. Psychopharmacol.8(S4), S52–S56 (1988).
   PubMed Web of Science ®Google Scholar
• Cardoso F, Vargas AP, Oliveira LD, Guerra AA, Amaral SV. Persistent Sydenham’s chorea. Mov. Disord.14(5), 805–807 (1999).
   PubMed Web of Science ®Google Scholar
• Goldman S, Wang C, Salgado MW, Greene PE, Kim M, Rapin I. Motor sterotypies in children with autism and other developmental disorders. Dev. Med. Child Neurol.51(1), 30–38 (2009).
   PubMed Web of Science ®Google Scholar
• Harris KM, Mahone EM, Singer HS. Nonautistic motor stereotypies: clinical features and longitudinal follow-up. Pediatr. Neurol.38(4), 267–272 (2008).
   Google Scholar
• Freeman RD, Soltanifar A, Baer S. Stereotypic movement disorder: easily missed. Dev. Med. Child Neurol. DOI: 10.111/j.1469-8749.2010.03627.x (2010) (Epub ahead of print).
   Google Scholar
• Mahone EM, Bridges D, Prahme C, Singer HS. Repetitive arm and hand movements (complex motor stereotypies) in children. J. Pediatr.145(3), 391–395 (2004).
   Google Scholar
• Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Ann. Neurol. (2010) (In press).
   Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement – a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol.3, 138–148 (2006).
   PubMedGoogle Scholar
• Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J. Clin. Pharmacol.48(3), 379–384 (2008).
   PubMed Web of Science ®Google Scholar
• Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Arch. Int. Med.149(11), 2386–2392 (1989).
   Google Scholar
• Dean CE, Thuras PD. Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br. J. Psychiatry194(4), 360–364 (2009).
   PubMed Web of Science ®Google Scholar
• Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J. Clin. Psychiatry65(S9), S16–S20 (2004).
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatr.3(2), 123–134 (1998).
   PubMed Web of Science ®Google Scholar
• Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J. Child Adolesc. Psychopharmacol.17(5), 647–656 (2007).
   PubMed Web of Science ®Google Scholar
• Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry21(2), 151–156 (2008).
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry161(3), 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology48(2), 358–362 (1997).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol.8(9), 844–856 (2009).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am. J. Psychiatry156(8), 1279–1281 (1999).
   PubMed Web of Science ®Google Scholar
• Vuong K, Hunter CB, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov. Disord.19(S9), 422 (2004).
   Google Scholar
• Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev. Neurother.6(1), 7–17 (2006).
   PubMedGoogle Scholar
• Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord.22(2), 193–197 (2007).
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther.31(1), 11–19 (2010).
   PubMed Web of Science ®Google Scholar
• Franzini A, Marras C, Ferroli P et al. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. A report of two cases. J. Neurosurg.102(4), 71–725 (2005).
   Google Scholar
• Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol. Scand.119(4), 269–273 (2009).
   PubMed Web of Science ®Google Scholar
• Aberg K, Adkins DE, Bukszar J et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol. Psychiatry67(3), 279–282 (2010).
   PubMed Web of Science ®Google Scholar
• Tsai HT, Caroff SN, Miller DD et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am. J. Med. Genet. B Neuropsychiatr. Genet.153B(1), 336–340 (2010).
   PubMed Web of Science ®Google Scholar
• Novak G, Gallo A, Zai CC et al. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr. Genet.20(1), 39–43 (2010).
   Google Scholar
• Wilffert B, Al Hadithy AF, Sing VJ et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African–Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J. Psychopharmacol.23(6), 652–659 (2009).
   PubMed Web of Science ®Google Scholar
• Al Hadithy AF, Ivanova SA, Pechlivanoglou P et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog. Neuropsychopharmacol. Biol. Psychiatry33(3), 475–481 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Janabi I, Arranz MJ, Blakemore Al et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr. Genet.19(6), 305–311 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang XY, Xiu MH, Chen DC et al. Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. J. Psychiatr. Res.144(7), 429–433 (2009).
   Google Scholar
• Zai CC, Tiwari AK, Basile V et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J.9(3), 168–174 (2009).
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, Basile V et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog. Neuropsychopharmacol. Biol. Psychiatry34(1), 50–56 (2010).
   PubMed Web of Science ®Google Scholar
• Zai CC, Tiwari AK, De Luca V et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur. Neuropsychopharmacol.19(5), 317–328 (2009).
   PubMed Web of Science ®Google Scholar
• De Luca V, Souza RP, Viggiano E et al.MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis. Schizophr. Res.110(1–3), 200–201 (2009).
   PubMed Web of Science ®Google Scholar
• Liou YJ, Chen ML, Wang YC et al. Analysis of genetic variations in the human Par-4 (PAWR) gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.150B(2), 439–440 (2009).
   PubMed Web of Science ®Google Scholar
• Park SW, Lee JG, Kong BG et al. Genetic association of BDNF val66met and GSK-3β-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin. Neurosci.63(4), 433–439 (2009).
   PubMed Web of Science ®Google Scholar
• Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between gluthathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum. Psychoharmacol.24(1), 55–60 (2009).
   PubMed Web of Science ®Google Scholar
• Tsai HT, North KE, West SL, Poole C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet.153B(1), 57–66 (2010).
   PubMed Web of Science ®Google Scholar
• Rizos EN, Chatziioannou S, Douzenis A et al. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan. Eur. Neuropsychopharmacol.20(2), 132–136 (2010).
   Google Scholar